Purpose: Cytarabine is considered the standard of care for induction therapy in patients with acute myeloid leukemia (AML) who are preparing for bone marrow transplant. Summary: We report a case of a 72-year-old female presenting to the intensive care unit with hepatic failure after high-dose cytarabine (HiDAC) for the treatment of relapsed AML. The patient's liver function tests (LFTs) were elevated acutely, with a mildly elevated bilirubin and a normal alkaline phosphatase. HiDAC was discontinued but her LFTs remained high for 9 days post discontinuation, and the patient eventually expired due to sepsis and multiple organ failure. We estimated the probability of the hepatotoxicity observed with HiDAC as probable based on a score of 5 on the Naranjo scale. Conclusion: Clinicians should be aware of the potential hepatotoxicity associated with HiDAC for patients with AML, specifically in the elderly population.
Purpose: Cytarabine is considered the standard of care for induction therapy in patients with acute myeloid leukemia (AML) who are preparing for bone marrow transplant. Summary: We report a case of a 72-year-old female presenting to the intensive care unit with hepatic failure after high-dose cytarabine (HiDAC) for the treatment of relapsed AML. The patient's liver function tests (LFTs) were elevated acutely, with a mildly elevated bilirubin and a normal alkaline phosphatase. HiDAC was discontinued but her LFTs remained high for 9 days post discontinuation, and the patient eventually expired due to sepsis and multiple organ failure. We estimated the probability of the hepatotoxicity observed with HiDAC as probable based on a score of 5 on the Naranjo scale. Conclusion: Clinicians should be aware of the potential hepatotoxicity associated with HiDAC for patients with AML, specifically in the elderly population.
Authors: R R Ellison; J F Holland; M Weil; C Jacquillat; M Boiron; J Bernard; A Sawitsky; F Rosner; B Gussoff; R T Silver; A Karanas; J Cuttner; C L Spurr; D M Hayes; J Blom; L A Leone; F Haurani; R Kyle; J L Hutchison; R J Forcier; J H Moon Journal: Blood Date: 1968-10 Impact factor: 22.113
Authors: M Tanaka; H Kanamori; S Yamaji; A Mishima; H Fujita; S Fujisawa; T Murata; H Koharazawa; M Matsuzaki; H Mohri Journal: Anticancer Drugs Date: 1999-03 Impact factor: 2.248
Authors: Juan Eduardo Megías-Vericat; Pau Montesinos; María José Herrero; Federico Moscardó; Virginia Bosó; David Martínez-Cuadrón; Luis Rojas; Rebeca Rodríguez-Veiga; Blanca Boluda; Luis Sendra; José Cervera; José Luis Poveda; Miguel Ángel Sanz; Salvador F Aliño Journal: Leuk Lymphoma Date: 2017-06-02